Tonix enrolls first patient in depression trial
Tonix Pharmaceuticals (NASDAQ:TNXP) said it enrolled the first patient in HORIZON, a Phase 2, randomized, double-blind, placebo-controlled study of TNX-102 SL 5.6 mg for adults with major depressive disorder.










